Comparison of Ovarian Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders

Phase 4

• Conditions: Infertility

• Registration Number: NCT01926210
• Lead Sponsor: Huang Rui

Brief Summary

This is a prospective, randomized clinical trial to compare the efficiency and safety of mild stimulation and controlled ovarian stimulation protocol on the treatment of POR. The randomization is achieved on the basis of a computer-generated randomization list in a 1:1 ratio.

Detailed Description

500 poor ovarian responders will be equally randomized to two different ovarian stimulation protocol arms,i.e, mild ovarian stimulation(experimental arm) or controlled ovarian stimulation(control arm). In experimental arm, patients will received letrozole 5mg per day from cycle day 3 to 7 and recombinant follicle-stimulating hormone (FSH) 150 international unit (IU) on day 4 and 6. The dose of recombinant FSH is adjusted according to the ovarian response and the gonadotropin-releasing hormone(GnRH)antagonist(Cetrotide) 0.25mg per day is administrated when the estradiol level reaches 200 pg/ml and the serum luteinizing hormone （LH）level rises above 2 times of basal LH level. In control arm,patients will be stimulated with short-acting GnRH agonist long protocol. After complete downregulation is achieved through GnRH-agonist, recombinant FSH 300 IU/d is given for 5 days, then the dose of recombinant FSH is adjusted according to ovarian response.

The clinical and ongoing pregnancy rate and other secondary outcome parameters are compared between these two groups.

Study Timeline

• Status Verified: 2013-08
• Study First Submitted: 2013-08-14
• Study First Submitted QC: 2013-08-16
• Study First Posted: 2013-08-20
• Last Update Submitted: 2013-08-20
• Last Update Posted: 2013-08-21
• Study Start: 2013-09
• Primary Completion: 2015-09
• Study Completion: 2016-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 500

Inclusion Criteria

• a. Poor ovarian responders b. Normal BMI (18-25 Kg/m2) c. Regular menstruation (with cycle 23-35 days)

Exclusion Criteria

• a. History of repeated IVF failure (previous IVF cycle >2) b. Serious adenomyosis c. Polycystic ovary syndrome(PCOS) patients d. History of allergic to ovulation induction medicines e. Abnormal uterine cavity, i.e, intrauterine adhesion f. Attending other clinical trials in the same period. g. History of systemic disease contradictory to COH or pregnancy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
clinical pregnancy rate	7 weeks

Secondary Outcome Measures

Name	Time	Method
live birth rate	10 months
Number of oocytes retrieved	3 weeks
Number of transferrable embryo	3 weeks
normal fertilization rate	3 weeks
implantation rate	7 weeks
ongoing pregnancy rate	3 months
Total dose of recombinant FSH consumption	3 weeks
length of stimulation	3 weeks
serum estradiol level	3 weeks
serum LH level	3 weeks
serum progesterone level	3 weeks
serum FSH level	3 weeks
FSH level in follicular fluid	3 weeks
LH level in follicular fluid	3 weeks
Estradiol level in the follicular fluid	3 weeks
progesterone level in follicular fluid	3 weeks
testerone level in the follicular fluid	3 weeks
anti-müllerian hormone (AMH)level in follicular fluid	3 weeks
Ovarian Hyperstimulation Syndrome (OHSS) rate	7 weeks

Trial Locations

Locations (1)

sixth affiliated hospital of Sun Yet-san University; 🇨🇳 Guangzhou, Guangdong, China